Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01076010 | An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | completed | Phase 3 | 277 | AVEO Pharmaceuticals, Inc.INDUSTRY | 15 | Oct 5, 2020 | clinicaltrials |
| NCT01774344 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma(RESORCE) | completed | Phase 3 | 573 | BayerINDUSTRY | 21 | Aug 20, 2020 |
| NCT00005970 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | completed | Phase 3 | 3,436 | National Cancer Institute (NCI)NIH | 4 | Aug 14, 2020 | clinicaltrials |
| NCT01583426 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)(GeparSepto) | completed | Phase 3 | 1,229 | GBG Forschungs GmbHOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT02545504 | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(GAMMA-1) | completed | Phase 3 | 432 | Gilead SciencesINDUSTRY | 16 | May 26, 2020 | clinicaltrials |
| NCT01216111 | Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) | completed | Phase 3 | 647 | Fudan UniversityOTHER | 0 | May 19, 2020 | clinicaltrials |
| NCT00339625 | Polyp Prevention Trial | completed | Phase 3 | 2,079 | National Cancer Institute (NCI)NIH | 1 | May 15, 2020 | clinicaltrials |
| NCT00272324 | Aspirin/Folate Prevention of Large Bowel Polyps | completed | Phase 2 / Phase 3 | 1,121 | Dartmouth-Hitchcock Medical CenterOTHER | 2 | Mar 13, 2020 | clinicaltrials |
| NCT03546842 | Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) | completed | Phase 3 | 201 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01833299 | Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma | completed | Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02961790 | Oxybutynin Chloride in Managing Hot Flashes | completed | Phase 3 | 150 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02385188 | Topical 5% Imiquimod Cream for Vulvar Paget's Disease | completed | Phase 3 | 25 | University Medical Center NijmegenOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00390455 | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | completed | Phase 3 | 295 | National Cancer Institute (NCI)NIH | 1 | Dec 20, 2019 | clinicaltrials |
| NCT02774187 | Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC | completed | Phase 3 | 247 | Sun Yat-sen UniversityOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT00908752 | Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC(BRISK TA) | completed | Phase 3 | 734 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 2, 2019 | clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | Oct 28, 2019 | clinicaltrials |
| NCT00917384 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | completed | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 30 | Sep 25, 2019 | clinicaltrials |
| NCT01287585 | Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy(ADI-PEG 20) | completed | Phase 3 | 636 | Polaris GroupINDUSTRY | 6 | Sep 6, 2019 | clinicaltrials |
| NCT00096278 | Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer | completed | Phase 3 | 2,710 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | completed | Phase 3 | 452 | National Cancer Institute (NCI)NIH | 2 | Jul 23, 2019 | clinicaltrials |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma(SEARCH) | completed | Phase 3 | 732 | BayerINDUSTRY | 26 | May 30, 2019 | clinicaltrials |
| NCT01229839 | Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC | completed | Phase 3 | 668 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01259414 | Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma | completed | Phase 3 | 812 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT01121393 | BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 364 | Boehringer IngelheimINDUSTRY | 3 | Dec 14, 2018 | clinicaltrials |
| NCT00068692 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | completed | Phase 3 | 225 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2018 | clinicaltrials |
| NCT00869206 | Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | completed | Phase 3 | 1,822 | Alliance for Clinical Trials in OncologyOTHER | 2 | Nov 7, 2018 | clinicaltrials |
| NCT00064077 | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix | completed | Phase 3 | 513 | Gynecologic Oncology GroupNETWORK | 1 | Oct 17, 2018 | clinicaltrials |
| NCT00606632 | Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody | completed | Phase 3 | 226 | Heidelberg Pharma AGINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02225470 | Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | completed | Phase 3 | 530 | Eisai Co., Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT03636620 | TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial(TACE+RFA) | completed | Phase 3 | 110 | Fudan UniversityOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | completed | Phase 3 | 345 | Boehringer IngelheimINDUSTRY | 25 | Apr 6, 2018 | clinicaltrials |
| NCT01829035 | A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC | completed | Phase 3 | 339 | National Cancer Center, KoreaOTHER_GOV | 1 | Mar 29, 2018 | clinicaltrials |
| NCT00443196 | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | completed | Phase 2 / Phase 3 | 150 | Pierian BiosciencesINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01265901 | IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma | completed | Phase 3 | 339 | Immatics Biotechnologies GmbHINDUSTRY | 11 | Oct 12, 2017 | clinicaltrials |
| NCT01901692 | Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion(START) | completed | Phase 2 / Phase 3 | 90 | Asan Medical CenterOTHER | 1 | Sep 18, 2017 | clinicaltrials |
| NCT03271918 | Cabergoline in Nonfunctioning Pituitary Adenomas | completed | Phase 3 | 140 | University of Sao Paulo General HospitalOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT00017004 | Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia | completed | Phase 3 | 114 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | completed | Phase 3 | 961 | GBG Forschungs GmbHOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT02883153 | Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 30 | Radboud University Medical CenterOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00548548 | A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer(AVAGAST) | completed | Phase 3 | 774 | Genentech, Inc.INDUSTRY | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01613846 | Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) | completed | Phase 3 | 544 | Technical University of MunichOTHER | 3 | Apr 20, 2017 | clinicaltrials |
| NCT01064310 | Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer(PISCES) | completed | Phase 3 | 169 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 17, 2017 | clinicaltrials |
| NCT00759109 | Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) | completed | Phase 3 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT00153816 | Vitamin D/Calcium Polyp Prevention Study | completed | Phase 2 / Phase 3 | 2,813 | Dartmouth-Hitchcock Medical CenterOTHER | 2 | Mar 15, 2017 | clinicaltrials |
| NCT01804829 | Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. | completed | Phase 3 | 80 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Oct 5, 2020source: clinicaltrials